AryoGen Pharmed

• NCT03425656

  Phase 3, Completed, 108 people, 7 Feb 2018

• Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women

  Phase 3, Status unknown, 190 people, 26 Sept 2017

• NCT03288987

  Phase 3, Completed, 126 people, 20 Sept 2017

Sources: clinicaltrials.gov